vs

Side-by-side financial comparison of BRANDYWINE REALTY TRUST (BDN) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

BRANDYWINE REALTY TRUST is the larger business by last-quarter revenue ($127.0M vs $74.7M, roughly 1.7× Health Catalyst, Inc.). BRANDYWINE REALTY TRUST runs the higher net margin — -38.4% vs -121.9%, a 83.5% gap on every dollar of revenue. On growth, BRANDYWINE REALTY TRUST posted the faster year-over-year revenue change (4.5% vs -6.2%). Over the past eight quarters, BRANDYWINE REALTY TRUST's revenue compounded faster (0.7% CAGR vs -0.0%).

Brandywine Realty Trust is a Philadelphia-based real estate investment trust (REIT) that invests in office buildings in Philadelphia, Washington, D.C., and Austin, Texas.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

BDN vs HCAT — Head-to-Head

Bigger by revenue
BDN
BDN
1.7× larger
BDN
$127.0M
$74.7M
HCAT
Growing faster (revenue YoY)
BDN
BDN
+10.7% gap
BDN
4.5%
-6.2%
HCAT
Higher net margin
BDN
BDN
83.5% more per $
BDN
-38.4%
-121.9%
HCAT
Faster 2-yr revenue CAGR
BDN
BDN
Annualised
BDN
0.7%
-0.0%
HCAT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BDN
BDN
HCAT
HCAT
Revenue
$127.0M
$74.7M
Net Profit
$-48.8M
$-91.0M
Gross Margin
Operating Margin
1.2%
-115.3%
Net Margin
-38.4%
-121.9%
Revenue YoY
4.5%
-6.2%
Net Profit YoY
-80.4%
-340.3%
EPS (diluted)
$-0.28
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BDN
BDN
HCAT
HCAT
Q1 26
$127.0M
Q4 25
$121.0M
$74.7M
Q3 25
$121.4M
$76.3M
Q2 25
$120.6M
$80.7M
Q1 25
$121.5M
$79.4M
Q4 24
$121.9M
$79.6M
Q3 24
$131.8M
$76.4M
Q2 24
$125.3M
$75.9M
Net Profit
BDN
BDN
HCAT
HCAT
Q1 26
$-48.8M
Q4 25
$-36.7M
$-91.0M
Q3 25
$-25.9M
$-22.2M
Q2 25
$-88.7M
$-41.0M
Q1 25
$-27.0M
$-23.7M
Q4 24
$-44.5M
$-20.7M
Q3 24
$-165.2M
$-14.7M
Q2 24
$30.2M
$-13.5M
Gross Margin
BDN
BDN
HCAT
HCAT
Q1 26
Q4 25
61.3%
Q3 25
62.6%
52.6%
Q2 25
62.4%
Q1 25
60.8%
Q4 24
61.2%
Q3 24
64.9%
47.5%
Q2 24
63.1%
Operating Margin
BDN
BDN
HCAT
HCAT
Q1 26
1.2%
Q4 25
22.8%
-115.3%
Q3 25
20.8%
-22.9%
Q2 25
-34.3%
-46.0%
Q1 25
12.5%
-25.4%
Q4 24
18.0%
-22.0%
Q3 24
-7.2%
-17.9%
Q2 24
15.5%
-20.8%
Net Margin
BDN
BDN
HCAT
HCAT
Q1 26
-38.4%
Q4 25
-30.3%
-121.9%
Q3 25
-21.3%
-29.1%
Q2 25
-73.5%
-50.8%
Q1 25
-22.2%
-29.9%
Q4 24
-36.5%
-26.0%
Q3 24
-125.4%
-19.3%
Q2 24
24.1%
-17.8%
EPS (diluted)
BDN
BDN
HCAT
HCAT
Q1 26
$-0.28
Q4 25
$-0.21
$-1.29
Q3 25
$-0.15
$-0.32
Q2 25
$-0.51
$-0.59
Q1 25
$-0.16
$-0.35
Q4 24
$-0.25
$-0.33
Q3 24
$-0.96
$-0.24
Q2 24
$0.17
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BDN
BDN
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$36.2M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
Total Assets
$3.6B
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BDN
BDN
HCAT
HCAT
Q1 26
$36.2M
Q4 25
$32.3M
$95.7M
Q3 25
$75.5M
$91.5M
Q2 25
$122.6M
$97.3M
Q1 25
$29.4M
$342.0M
Q4 24
$90.2M
$392.0M
Q3 24
$36.5M
$387.3M
Q2 24
$30.4M
$308.3M
Total Debt
BDN
BDN
HCAT
HCAT
Q1 26
Q4 25
$2.6B
$153.3M
Q3 25
$2.3B
$153.1M
Q2 25
$2.3B
$153.0M
Q1 25
$2.2B
$382.9M
Q4 24
$2.2B
$382.4M
Q3 24
$2.3B
$345.0M
Q2 24
$2.2B
Stockholders' Equity
BDN
BDN
HCAT
HCAT
Q1 26
Q4 25
$792.7M
$245.8M
Q3 25
$841.5M
$331.9M
Q2 25
$879.8M
$347.5M
Q1 25
$993.6M
$376.8M
Q4 24
$1.0B
$365.2M
Q3 24
$1.1B
$355.0M
Q2 24
$1.3B
$357.0M
Total Assets
BDN
BDN
HCAT
HCAT
Q1 26
$3.6B
Q4 25
$3.6B
$502.6M
Q3 25
$3.3B
$587.1M
Q2 25
$3.4B
$616.2M
Q1 25
$3.4B
$891.5M
Q4 24
$3.5B
$858.9M
Q3 24
$3.6B
$813.0M
Q2 24
$3.8B
$691.7M
Debt / Equity
BDN
BDN
HCAT
HCAT
Q1 26
Q4 25
3.23×
0.62×
Q3 25
2.70×
0.46×
Q2 25
2.63×
0.44×
Q1 25
2.23×
1.02×
Q4 24
2.13×
1.05×
Q3 24
2.06×
0.97×
Q2 24
1.73×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BDN
BDN
HCAT
HCAT
Operating Cash FlowLast quarter
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BDN
BDN
HCAT
HCAT
Q1 26
Q4 25
$116.7M
$9.9M
Q3 25
$47.5M
$-464.0K
Q2 25
$34.4M
$-9.0M
Q1 25
$6.3M
$280.0K
Q4 24
$181.1M
$-3.5M
Q3 24
$52.2M
$6.2M
Q2 24
$48.2M
$1.6M
Free Cash Flow
BDN
BDN
HCAT
HCAT
Q1 26
Q4 25
$9.6M
Q3 25
$-719.0K
Q2 25
$-9.2M
Q1 25
$-390.0K
Q4 24
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
FCF Margin
BDN
BDN
HCAT
HCAT
Q1 26
Q4 25
12.9%
Q3 25
-0.9%
Q2 25
-11.4%
Q1 25
-0.5%
Q4 24
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Capex Intensity
BDN
BDN
HCAT
HCAT
Q1 26
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.8%
Q4 24
0.5%
Q3 24
0.9%
Q2 24
0.4%
Cash Conversion
BDN
BDN
HCAT
HCAT
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BDN
BDN

Rents$120.7M95%
Third party management fees, labor reimbursement and leasing$4.7M4%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons